Na+/H+ exchanger regulatory factor 1 overexpression suppresses the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells by downregulating Akt phosphorylation

Zhang,Xibo; Liu,Junjian; Li,Zhonglian

doi:10.3892/ol.2018.8289

Na+/H+ exchanger regulatory factor 1 overexpression suppresses the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells by downregulating Akt phosphorylation

Authors:
- Xibo Zhang
- Junjian Liu
- Zhonglian Li
View Affiliations

Affiliations: Department of Hepatopancreatobiliary Surgery, Tianjin Nankai Hospital, Tianjin 300100, P.R. China
Published online on: March 16, 2018 https://doi.org/10.3892/ol.2018.8289
Pages: 7725-7729
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Na+/H+ exchanger regulatory factor 1 (NHERF1) is reported to be associated with the development of numerous types of tumor; however, its effects on the metastasis of pancreatic adenocarcinoma are not fully understood. In the present study, it was revealed that the expression level of NHERF1 in pancreatic adenocarcinoma is decreased compared with normal pancreatic tissue based on the analysis of a protein expression database. The present study was undertaken in order to investigate the potential effects of NHERF1 overexpression on the malignant phenotype of MIAPaCa‑2 pancreatic adenocarcinoma cells. NHERF1 was stably overexpressed in this cell line, and Cell Counting Kit‑8, wound healing and Transwell assays were used to detect the proliferative and migratory abilities of the cells. NHERF1 overexpression suppressed proliferation in the MIAPaCa‑2 cell line compared with empty vector‑transfected (negative control) cells. Additionally, NHERF1 overexpression significantly inhibited the migration of MIAPaCa‑2 cells. The results of a western blot analysis identified that NHERF1 overexpression markedly decreased the expression of phosphorylated‑protein kinase B (p‑Akt), while no significant difference was observed between untransfected and negative control cells. Taken together, these results suggested that NHERF1 may be able to inhibit the proliferation and migration and alter the malignant phenotype of pancreatic adenocarcinoma cells via reduction of p‑Akt levels. These findings indicate a potential novel approach to the treatment of pancreatic adenocarcinoma.

View Figures

View References

1	Mann KM, Ying H, Juan J, Jenkins NA and Copeland NG: KRAS-related proteins in pancreatic cancer. Pharmacol Ther. 168:29–42. 2016. View Article : Google Scholar : PubMed/NCBI
2	Vijayvergia N and Cohen SJ: Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: Are we any closer? J Gastrointest Oncol. 7:727–737. 2016. View Article : Google Scholar : PubMed/NCBI
3	Miyoshi E and Kamada Y: Application of glycoscience to the early detection of pancreatic cancer. Cancer Sci. 107:1357–1362. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cheng S, Li Y, Yang Y, Feng D, Yang L, Ma Q, Zheng S, Meng R, Wang S, Wang S, et al: Breast cancer-derived K172N, D301V mutations abolish Na⁺/H⁺ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling. FEBS Lett. 587:3289–3295. 2013. View Article : Google Scholar : PubMed/NCBI
5	Shibata T, Chuma M, Kokubu A, Sakamoto M and Hirohashi S: EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology. 38:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
6	Fraenzer JT, Pan H, Minimo L Jr, Smith GM, Knauer D and Hung G: Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol. 23:1493–1500. 2003.PubMed/NCBI
7	Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ma Q, Jiao Y, Hao Y, Yan S, Lyu N, Gao H, Li D, Liu Q, Zheng J and Song N: Targeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cells. Oncol Lett. 11:1149–1154. 2016. View Article : Google Scholar : PubMed/NCBI
9	Chen X, Yang H, Zhang S, Wang Z, Ye F, Liang C, Wang H and Fang Z: A novel splice variant of supervillin, SV5, promotes carcinoma cell proliferation and cell migration. Biochem Biophys Res Commun. 482:43–49. 2016. View Article : Google Scholar : PubMed/NCBI
10	Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, et al: Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor extrinsic and intrinsic activities. Mol Cancer Ther. 16:344–356. 2016. View Article : Google Scholar : PubMed/NCBI
11	McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, et al: Effects of mutations in Wnt/beta-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta. 1863:2942–2976. 2016. View Article : Google Scholar : PubMed/NCBI
12	Rumman M, Jung KH, Fang Z, Yan HH, Son MK, Kim SJ, Kim J, Park JH, Lim JH and Hong S: HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Oncotarget. 7:78029–78047. 2016. View Article : Google Scholar : PubMed/NCBI
13	Li H, Zhang B, Liu Y and Yin C: EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med Oncol. 31:1622014. View Article : Google Scholar : PubMed/NCBI
14	Bellizzi A, Greco MR, Rubino R, Paradiso A, Forciniti S, Zeeberg K, Cardone RA and Reshkin SJ: The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. Int J Oncol. 46:1214–1224. 2015. View Article : Google Scholar : PubMed/NCBI
15	James MF, Beauchamp RL, Manchanda N, Kazlauskas A and Ramesh V: A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci. 117:2951–2961. 2004. View Article : Google Scholar : PubMed/NCBI
16	Curto M, Cole BK, Lallemand D, Liu CH and McClatchey AI: Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 177:893–903. 2007. View Article : Google Scholar : PubMed/NCBI
17	Meng R, Qin Q, Xiong Y, Wang Y, Zheng J, Zhao Y, Tao T, Wang Q, Liu H, Wang S, et al: NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer. Oncotarget. 7:54983–54997. 2016. View Article : Google Scholar : PubMed/NCBI
18	Georgescu MM, Gagea M and Cote G: NHERF1/EBP50 suppresses Wnt-beta-catenin pathway-driven intestinal neoplasia. Neoplasia. 18:512–523. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lim HJ, Wang X, Crowe P, Goldstein D and Yang JL: Targeting the PI3K/PTEN/AKT/mTOR pathway in treatment of sarcoma cell lines. Anticancer Res. 36:5765–5771. 2016. View Article : Google Scholar : PubMed/NCBI
20	Xiao J, Lin HY, Zhu YY, Zhu YP and Chen LW: miR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
21	Peng Z, Wang Q, Zhang Y, He J and Zheng J: EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients. Int J Oncol. 49:1737–1745. 2016. View Article : Google Scholar : PubMed/NCBI